Novartis to Buy Tourmaline Bio in $1.4B Acquisition Deal
Novartis has confirmed it will acquire Tourmaline Bio in a deal valued at $1.4 billion. The agreement highlights Novartis’s ambition to expand its oncology pipeline and deepen its commitment to data-driven medicine. This acquisition also strengthens Novartis’s reputation in the stock market, particularly among those tracking AI stocks that blend biotechnology with digital innovation. It…